Amicus Therapeutics Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Decisions with the Full Value Chain Report
This Amicus Therapeutics Value Chain Analysis helps you quickly understand how the company creates value across support and primary activities in one structured framework. This page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Amicus Therapeutics runs firm infrastructure from its Princeton headquarters, where finance, legal, compliance, quality, and regulatory teams sit under one roof. That setup fits a rare-disease business with 2 marketed therapies and a small patient base, because capital must be tight and decisions must move fast. Central oversight also helps keep U.S. and global regulatory work aligned across launches and life-cycle work.
Human Resource Management
Amicus Therapeutics's Human Resource Management must hire people with rare-disease, regulatory, medical affairs, and specialty commercial experience. That matters because Fabry and Pompe programs need teams that can handle genetic testing, payer access, and patient support without gaps. In 2025, the workforce priority is talent that can move fast across science, compliance, and access work.
Technology Development
Amicus Therapeutics uses technology development to push precision medicine, chaperone science, biomarker work, and gene-focused therapy research for rare genetic disorders. In fiscal 2025, research and development expense was about $190 million, showing the scale of this R&D engine behind Galafold and enzyme-based programs. This work helps Amicus Therapeutics improve patient selection and defend differentiation in small orphan markets, where even small gains in biomarker fit can matter a lot.
Procurement
Amicus Therapeutics depends on qualified suppliers, contract manufacturers, and testing partners for APIs, biologic inputs, packaging, and fill-finish work. With a 2-product portfolio in 2025, tight procurement control helps reduce single-source risk, protect supply continuity, and keep fixed costs lower while volumes stay concentrated.
Good procurement also supports quality and release timing, which matters in rare-disease therapies where delays can hit revenue fast. It gives Amicus Therapeutics more flexibility to shift spend across partners without locking into a heavy cost base.
Amicus Keeps Rare-Disease Support Lean as R&D Hits $190M
Amicus Therapeutics kept support activities lean in 2025, with headquarters-based finance, legal, compliance, quality, and regulatory teams backing a 2-product rare-disease portfolio. That structure matters because 2025 research and development expense was about $190 million, so overhead, hiring, and vendor control had to stay tight. Procurement and external manufacturing also helped protect supply continuity and release timing for Galafold and Pompe work.
| 2025 support activity | Key data |
|---|---|
| R&D expense | About $190 million |
| Portfolio | 2 marketed therapies |
| Operating focus | Rare-disease scale control |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Amicus Therapeutics sources specialty inputs through a controlled supplier network, and its 2025 filings show inventory of $166.3 million, which fits the tighter controls needed for both oral and biologic products. Inbound logistics must handle different storage, handling, and quality checks for these product forms, so supplier qualification and cold-chain discipline stay central. This setup helps protect supply reliability while supporting higher-value therapies with strict release standards.
Operations
Amicus Therapeutics creates value in Operations by tightly managing clinical development, regulatory execution, quality control, and supply planning for Galafold and Pombiliti/Opfolda. Because most manufacturing is outsourced, Amicus Therapeutics wins by coordinating two product chains well, not by running large plants. That model keeps fixed production assets light while protecting launch readiness, batch quality, and patient supply.
Outbound Logistics
Amicus Therapeutics uses specialty pharmacies and rare-disease channels to ship Galafold and Pombiliti/Opfolda, so outbound logistics is built for controlled dispensing and fast treatment start. With 2 marketed therapies in 2025, any delay can slow therapy initiation in very small patient pools. Order accuracy, cold-chain handling where needed, and patient onboarding matter because refill gaps can quickly hit adherence and access.
Marketing and Sales
Amicus Therapeutics markets Galafold and Pombiliti/Opfolda to a narrow base of genetic and metabolic disease specialists, so selling is tied to expert centers that diagnose rare patients and start therapy. In 2025, that model still depended on field teams, medical education, and genetic-testing awareness to move patients from suspicion to confirmed eligibility, which is key in Fabry and Pompe disease. This makes diagnosis support a direct revenue driver, not just a support activity.
Service
Amicus Therapeutics uses Service to keep patients on therapy after the prescription, with reimbursement help, adherence support, and medical information services. In rare disease, that work matters because missed doses and coverage delays can quickly break persistence and raise churn risk. It also reduces friction for physicians and payers by answering access and safety questions fast, which supports long-term use of Amicus Therapeutics treatments.
Amicus Therapeutics' rare-disease execution stays asset-light in 2025
Amicus Therapeutics' primary activities in 2025 were built around 2 marketed therapies, Galafold and Pombiliti/Opfolda, so every step centers on rare-disease execution. Operations stay asset-light because manufacturing is outsourced, while quality control, regulatory work, and supply planning protect launch readiness and patient supply. Outbound logistics and service depend on specialty-pharmacy access, reimbursement help, and adherence support to keep therapy starts and refills on track.
| 2025 driver | Value |
|---|---|
| Inventory | $166.3 million |
| Marketed therapies | 2 |
Preview Before You Purchase
Amicus Therapeutics Reference Sources
This is the actual Amicus Therapeutics Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see is exactly what you get. Once purchased, the complete in-depth version is unlocked immediately.
Frequently Asked Questions
Amicus Therapeutics' value chain is driven by rare-disease specialization. The company runs a 2-product commercial model around Fabry and Pompe, and that makes diagnosis, specialist prescribing, and reimbursement more important than mass-market scale. Precision R&D, access support, and outsourced manufacturing are the main levers that convert scientific work into revenue.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.